The Federal Circuit's affirmance permanently eliminates the $107.5M jury verdict and the patent infringement overhang on Tagrisso from these Wyeth patents. Tagrisso is a key AstraZeneca oncology product; this ruling removes a material IP risk. Monitor for any Wyeth petition for certiorari (unlikely given the fact-specific enablement holding) and for any remaining patent challenges on Tagrisso from other parties.
Drug in focus
AZN drug pipeline →Tagrisso
● Neutral Named in this court ruling- Impact
- Phase
- Approved
- Time to market
- Approved and marketed since 2015 (first FDA approval Nov 2015)
- Next catalyst
- None dated
What to watchTagrisso is AZN's largest drug at $7.3B in 2025 revenue, but it is already fully de-risked and commercialized. The near-term investor debate centers on how quickly J&J's Rybrevant/lazertinib combo erodes first-line share and how far label expansion (LAURA Stage III) boosts volume, gradual commercial trends, not binary events. Watch quarterly sales growth rates and the LAURA OS readout for the next meaningful update.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 10 $171.61entry
- T+1 · 4mo ago −1.25%α −0.48% · $169.47
- T+5 · 4mo ago −1.58%α −0.03% · $168.90
- T+20 · 3mo ago −5.94%α −8.36% · $161.42
- T+60 · 6w ago −8.79%α −11.42% · $156.53
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
The Federal Circuit affirmed the district court's grant of JMOL of invalidity for lack of enablement of Wyeth's asserted patents (U.S. Patent 10,603,314 and 10,596,162) covering methods of treating gefitinib/erlotinib-resistant NSCLC with irreversible EGFR inhibitors. The ruling permanently removes the patent infringement risk to AstraZeneca's Tagrisso (osimertinib) and vacates the $107.5M jury verdict against AstraZeneca, eliminating a material liability and IP overhang.
Court Ruling Details
Key Facts
- Federal Circuit affirmed district court's JMOL of invalidity for lack of enablement of Wyeth's asserted claims in U.S. Patents 10,603,314 and 10,596,162
- The ruling vacates the $107,500,000 jury verdict against AstraZeneca for induced infringement of Tagrisso (osimertinib)
- The patents claimed methods of treating gefitinib/erlotinib-resistant NSCLC with irreversible EGFR inhibitors; the court found the specification failed to enable a daily unit dosage for human patients without undue experimentation
- The Federal Circuit affirmed that the specification provided no working examples of unit dosages in patients and disclosed dosage ranges that were toxic for at least two of the three preferred compounds
- This is a final appellate ruling from the Federal Circuit, the authoritative court for patent appeals, and is not subject to further appeal as of right
Financial Impact
Vacates $107,500,000 jury verdict against AstraZeneca and permanently removes patent infringement risk on Tagrisso (osimertinib) from these Wyeth patents
Risk Factors
- Wyeth could petition for certiorari to the Supreme Court, though the fact-specific enablement holding makes this unlikely
- Other patent challenges to Tagrisso from different patent holders remain possible
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-f42fbd41d9-AZN |
Track record
77 reports on AZN
19 of 37 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 29 of 37 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
- Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.02 −0.82% settles Nov 23
- Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.02 −0.70% settles Nov 23
- Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.02 −0.58% settles Nov 23
- Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.02 −1.51% ▼ −1.32% −4.61% vs SPY
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
- Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.02 −1.41% ▼ −0.12% +2.59% vs SPY
- Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.02 +8.20% ▲ +8.11% +10.10% vs SPY
- Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.02 +6.63% ▲ +0.51% −0.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers